Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
10-Sep-2018
Ceasing to be a substantial holder
6-Sep-2018
Bard1 Ovarian Test Results
31-Aug-2018
Appendix 4E
21-Aug-2018
Final Director's Interest Notice
13-Aug-2018
Death of Non-Executive Director
1-Aug-2018
Quarterly Activities Report and Appendix 4C
12-Jul-2018
US Patent Issued Protecting BARD1 Ovarian Test
21-Jun-2018
Appendix 3B Release of Securities from Escrow
19-Jun-2018
Improved Performance of BARD1 Ovarian Test
8-Jun-2018
Notice under ASX Listing Rule 3.10A
Previous
1
2
3
4
5
6
Next
